Clinical study of injection of mouse nerve growth factor (Jin Lujie) in the treatment of autism spectrum disorder

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051546

Enrollment

Unknown

Registered

2021-09-26

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ASD

Interventions

Experimental group:Injection nerve growth factor

Control group:Routine education and training

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All meet the ASD diagnostic and grading standards formulated by DSM-5; 2. Age 2-6 years old; 3. The legal guardian has informed consent, signed the informed consent form, and can accept the prescribed 3-month treatment and requirements; 4. Gesell developmental scale test: comprehensive developmental quotient <75 points.

Exclusion criteria

Exclusion criteria: 1. Abnormal liver and kidney function; 2. Genetic metabolic diseases such as: Rett syndrome, Fragile X syndrome; 3. Those suffering from serious systemic diseases, blood system diseases and infectious diseases; 4. Epilepsy; 5. Those who are allergic to mouse nerve growth factor; 6. The information is incomplete due to various reasons.

Design outcomes

Primary

Measure	Time frame
Autistic Children's Behavior Inventory;Childhood Autism Rating Scale;Autism Treatment Evaluation Checklist, ATEC;Diffusion Tensor Imaging;Gesell Developmental Assessment Scale;liver function;renal function;	—

Countries

China

Contacts

Public ContactMa Bingxiang

The First Affiliated Hospital of Henan University of Chinese Medicine

mbx1963@126.com+86 13592601575

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026